Goldman Sachs Starts Cerner (CERN) at Conviction Buy
Tweet
Share
E-mailGet Alerts CERN Hot Sheet
Price: $94.92 --0%
Rating Summary:
8 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Rating Summary:
8 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Join SI Premium – FREE
Goldman Sachs initiates coverage on Cerner (NASDAQ: CERN) with a Conviction Buy list rating and $78 priced target.
The firm said the company "offers investors high-quality exposure to HCIT industry growth and is ideally positioned to be a market share gainer."
Goldman said the company will be a beneficiary of the stimulus-driven growth curve of HCIT penetration U.S.
They see accelerating revenue growth over the next 3 years versus the consensus which sees decelerating growth. Their 2013 EPS estimate is 13% above the consensus.
For more ratings news on Cerner click here and for the rating history of Cerner click here.
Shares of Cerner closed at $61.80 yesterday.
The firm said the company "offers investors high-quality exposure to HCIT industry growth and is ideally positioned to be a market share gainer."
Goldman said the company will be a beneficiary of the stimulus-driven growth curve of HCIT penetration U.S.
They see accelerating revenue growth over the next 3 years versus the consensus which sees decelerating growth. Their 2013 EPS estimate is 13% above the consensus.
For more ratings news on Cerner click here and for the rating history of Cerner click here.
Shares of Cerner closed at $61.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
- Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight
- Benchmark Starts Allegro MicroSystems (ALGM) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Goldman Sachs Conviction Buy List, Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
